A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001. by Oronsky, Bryan et al.
UC San Diego
UC San Diego Previously Published Works
Title
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer 
Patient After Priming with RRx-001.
Permalink
https://escholarship.org/uc/item/47z2q60k
Authors
Oronsky, Bryan
Caroen, Scott
Zeman, Karen
et al.
Publication Date
2016
DOI
10.4137/cmo.s40429
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
105CliniCal MediCine insights: OnCOlOgy 2016:10
Introduction
As a major cause of treatment failure, therapeutic tumor 
resistance, whether innate or acquired, is mediated by mul-
tifactorial compensatory and adaptive events,1 and following 
the known principle of “fighting fire with fire”, multifactorial 
inactivation or inhibition is likely required to bypass or reverse 
it. These multiple events,2 too numerous to list in full here, 
which include the upregulation of antioxidant response path-
ways, drug efflux, poor blood flow, hypoxia, acidity, genetic 
mutations, epigenetic modifications, enhanced DNA repair, 
quiescence, and inactivation of apoptotic proteins, lead to 
an insidious drug-resistant state,3 not only to one particular 
therapeutic regimen per se but also to related ones in a phe-
nomenon known as cross- or pan-resistance,4 resulting in an 
ever-increasing uphill battle for the treating oncologist. Such 
pleiotropy is an argument in favor of the use of combination 
therapy; however, additive or synergistic therapeutic effects 
may be accompanied by additive or synergistic toxicities, ren-
dering the combination infeasible due to safety concerns and/
or poor compliance. An alternative to combination therapy is 
a multitargeted single agent,5 such as RRx-001.
RRx-001 is a systemically nontoxic reactive oxygen 
species-mediated epi-immunotherapeutic agent, acting on 
DNA methyltransferases and histone deacetlyases6 with vas-
cular normalizing properties7 that multifactorially reverse the 
tumor cell resistance8 and chemo–immuno–radiosensitize 
the cancer cells.9–11 A lack of toxicity is a major advantage 
in this context, because approved epigenetic inhibitors, such 
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AbstrAct: As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known 
cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and 
many other tumor types, given a response rate of less than 10% and an overall survival of less than six months. It was broadly classified into three groups 
based on the initial response to cisplatin/etoposide therapy, platinum-refractory, platinum-resistant, and platinum-sensitive, extensive stage SCLC inevi-
tably relapses, at which point the only standard options are to rechallenge with the first-line chemotherapeutic regimen in the case of sensitive disease or 
to start the topoisomerase I inhibitor, topotecan. Sensitive disease is defined by a response to the first-line therapy and a treatment-free interval of at least 
90 days, while the definitions of refractory and resistant disease, respectively, are nonresponse to the first-line treatment or relapse within 90 days. As an 
important predictor of response to the second-line treatment, the clinical cutoff of three months (or two months in some cases) for resistant and sensi-
tive disease, which along with performance status prognostically separates patients into high- and low-risk categories, dictates subsequent management. 
This case report presents a resistant SCLC patient enrolled on a Phase II clinical trial called QUADRUPLE THREAT (formerly TRIPLE THREAT; 
NCT02489903) who responded to reintroduced platinum doublets after sequential priming with the resistance-reversing epi-immunotherapeutic agent, 
RRx-001. In the QUADRUPLE THREAT clinical trial, both during priming with RRx-001 and during sequential treatment with platinum doublets, 
the patient maintained a good quality of life and performance status.
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as the hypomethylating agents, azacitidine and decitabine, 
which have been administered adjunctively to reverse broad- 
spectrum chemoresistance, are associated with prolonged 
dose-limiting myelosuppression and gastrointestinal toxicity 
even at lower doses.12
In contrast, the nonmyelosuppressive properties of 
RRx-001,6 which generally lead to the recovery of normal 
blood counts during treatment, are the basis for a sequential 
schedule of RRx-001 administered until radiologic progres-
sion followed by introduction or reintroduction of the first-
line chemotherapy (Fig. 1).
In the context of treatment of small cell lung cancer 
(SCLC), non-SCLC (NSCLC), or high-grade neuroen-
docrine tumor (HGNET) patients, the first-line therapy is 
typically a platinum doublet with platinum (cisplatin or car-
boplatin) matched with etoposide (EP), nab-paclitaxel, or 
paclitaxel. Food and Drug Administration-approved salvage 
therapies that would be available to this patient population 
include docetaxel for NSCLC, topotecan for SCLC, and none 
for HGNET.
In addition, serial tumor biopsies have demonstrated that 
RRx-001 initiates an immunologically driven inflammatory 
and edematous response9,13 and not uncommonly misinter-
preted as tumor progression on 6- or 8-week scans,14 which 
is potentially a further justification for sequential dosing of 
RRx-001 followed by chemotherapy, since it may take up to 
12 weeks to resolve the inflammation and edema and to shrink 
or stabilize the tumor.
In the four-arm sequentially designed Phase II clinical 
trial called QUADRUPLE THREAT (formerly TRIPLE 
THREAT; NCT02489903), patients with SCLC, NSCLC, 
HGNET, and resistant/refractory ovarian tumors (hence, 
the QUADRUPLE in the title) are reintroduced to the first-
line platinum doublets following disease progression on 
RRx-001 (Fig. 2).
Of the tumors studied in this trial, recurrent resistant 
SCLC (rSCLC) arguably has the most aggressive, drug- 
resistant phenotype with a response rate (RR) of less than 
10%15,16 and an overall survival of less than six months.17 
Therefore, resensitization to platinum doublets in this patient 
population is a virtual impossibility.
Herein, we present an 82-year-old rSCLC patient who 
achieved a partial response on platinum doublets after 12 weeks 
of priming with RRx-001 in the QUADRUPLE THREAT 
clinical trial. After over three decades of no new treatments 
in SCLC,18 any favorable response is a potentially publishable 
case, especially in the recurrent-resistant setting,19 where
•	 second-line treatments are not approved (although topo-
tecan is commonly used)20,21;
•	 the five-year survival rate has remained stagnant at 5%;
•	 topotecan yields RRs that range dismally from 6.4% to 
8.6%, and the median overall survival has never exceeded 
5.7 months22;
•	 rapid clinical deterioration is the rule.
Rather than this expected downward spiral of functional 
decline, the patient has maintained a good performance sta-
tus over the course of his participation in the QUADRUPLE 
THREAT clinical trial.
case
The patient is a 82-year-old white male diagnosed in June 
2015 with extrapulmonary SCLC, manifesting HPV-positive 
small cell carcinoma at the left base of the tongue metastatic 
to the liver (clinical stage T3, N0, and M1). The patient ini-
tially received six cycles of carboplatin–EP on July 7, 2015, but 
progressed one month after its completion, meeting the defini-
tion of resistant disease. The platinum doublets were followed 
on December 12th, 2015, by palliative radiotherapy (XRT) to 
the neck. On January 14, 2016, having histologically or cyto-
logically confirmed SCLC with a metastatic liver lesion as the 
primary lesion, the patient enrolled on NCT02489903 and 
began weekly intravenous treatment with 4 mg RRx-001 coin-
fused with autologous blood. At the time of enrollment, his 
performance status was ECOG 1 with fatigue and decreased 
appetite as his chief complaints. Within one week of starting 
RRx-001, the patient reported normalization of energy and 
appetite, resulting in an improvement of general demeanor 
and level of alertness. No systemic side effects related to treat-
ment were observed. The first six-week restaging computerized 
tomography (CT) scan demonstrated stable disease, which 
resulted in the continuation of therapy. However, the 12-week 
CT scan demonstrated progressive disease per RECIST v.1.1 
criteria. At this point, per protocol, RRx-001 was discontinued, 
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figure 1. Bone marrow function recovery period with RRx-001 treatment 
prior to reintroduction of platinum doublets.
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figure 2. schematic representation of QUadRUPle thReat study 
(nCt02489903).
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and carboplatin–EP was reintroduced with the plan to repeat 
CT scans after every two cycles (six weeks). To date, the EP 
regimen has been very well tolerated with no myelosuppres-
sion. The CT scan at week 6 was classified as a partial response 
with a 32% reduction in target liver lesions (Fig. 3).
The management plan for this patient is to continue 
treatment with carboplatin–EP for up to six cycles, with 
repeat CT every six weeks until disease progression or 
intolerable toxicity.
discussion
Progress in SCLC, a relentlessly aggressive, rapidly metasta-
sizing, and highly fatal neoplasm,23 has remained lamentably 
stagnant for decades, and an active, nontoxic chemotherapeutic 
regimen, especially in the resistant/recurrent setting, is nota-
bly lacking for this disease. The rarity of desirable responses 
in rSCLC coupled with a lack of effective, nontoxic therapies 
is the motivation for this case report, which describes clini-
cal benefit in the form of a .30% reduction in tumor sizes 
after only two cycles (six weeks) of reintroduced platinum 
therapy following a priming period with RRx-001 and main-
tenance/improvement of ECOG performance status. While it 
is manifestly too early to generalize and extrapolate the effi-
cacy of RRx-001 in SCLC from this patient, partial responses 
have also been reported for two other rSCLC patients in the 
QUADRUPLE THREAT trial,9 which suggests a develop-
ing trend.
Two of the key RRx-001 antiresistance mechanisms are 
epigenetic inhibition24 and immune stimulation9,13; however, a 
hallmark of any successful sensitizer is target promiscuity, and 
RRx-001, which is no exception,25 also possesses prooxidant, 
apoptotic,24,26 antiangiogenic,27 and P-gp inhibitory proper-
ties. Recently published case reports of partial responses in 
NSCLC13,28 in the QUADRUPLE THREAT trial raise the 
possibility that RRx-001 may broadly alter the multidrug 
resistance phenotype, sensitizing or resensitizing heavily pre-
treated patients with platinum-based resistance in other non-
thoracic tumor types where doublet regimens are approved 
or considered the mainstay of care, such as gastroesophageal, 
transitional cell and bladder cancer, cervical, testicular, and 
head and neck cancers. Additional studies are needed in sup-
port of this hypothesis and early observations.
conclusion
This case report describes a new rechallenge strategy with 
RRx-001 in the management of a patient with recurrent 
SCLC/rSCLC, a tumor type known for its poor clinical 
response to chemotherapy. Additional cases are needed to 
determine whether RRx-001 is beneficial in SCLC.
statement of ethics
The patient described in this case report has given his written, 
informed consent to participate in the TRIPLE THREAT 
clinical study (NCT02489903), and for publication of details 
figure 3. Ct scan performed on august 24, 2011, demonstrating liver metastases with the maximum diameters of 5.94 and 8.06 cm (left) that showed 
significant shrinkage to 3.70 and 5.82 cm (right).
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and images of his case in this report. This study protocol has 
been approved by the Walter Reed National Military Medi-
cal Center Institutional Review Board. The research was con-
ducted in accordance with the principles of the Declaration 
of Helsinki.
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